Advances in therapeutic oligonucleotide conjugates
Abstract
Oligonucleotide therapeutics (ONTs) have revolutionized the medical landscape by enabling the precise modulation of genetic pathways. This perspective highlights the major conjugation strategies for ONTs, using antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) as representative modalities. We describe diverse classes of targeting ligands, including small molecules, cell-penetrating peptides (CPPs), antibodies, and aptamers. For example, triantennary N-acetylgalactosamine (GalNAc) conjugation has enabled a number of approved oligonucleotide therapeutics. Meanwhile, other emerging conjugation technologies have expanded oligonucleotide delivery to extrahepatic tissues to address a broader range of diseases. We further summarize the clinical translation of these delivery platforms, highlighting approved therapeutics alongside emerging clinical candidates. Finally, we provide an outlook on challenges and opportunities for the next generation of oligonucleotide therapeutics.
Related
- Cell-resolved pharmacodynamic profiling reveals tissue- and cell-population-specific activity of antisense oligonucleotide chemical conjugates in vivo
- Modular multifunctional 5HP2O linkers for the versatile assembly of protein-oligonucleotide conjugates
- Beyond Targeted Delivery: The Emerging Immunomodulatory Landscape of Antibody-Oligonucleotide Conjugates
- Enhancing the efficacy of siRNA Antibody Oligonucleotide Conjugates (AOCs) through chemical design
- Spatial multi-omics analyses of the tumor immune microenvironment: advances and novel therapeutic avenues.
BibTeX
@article{zheng2026advances,
title = {{Advances in therapeutic oligonucleotide conjugates}},
author = {Ya Ying Zheng and Yonger Xue and Xucheng Hou and Yizhou Dong},
journal = {Aaps Open},
year = {2026},
month = nov,
doi = {10.1186/s41120-026-00209-8},
url = {https://doi.org/10.1186/s41120-026-00209-8},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Advances in therapeutic oligonucleotide conjugates
AU - Ya Ying Zheng
AU - Yonger Xue
AU - Xucheng Hou
AU - Yizhou Dong
PY - 2026
DA - 2026/11/02
JO - Aaps Open
DO - 10.1186/s41120-026-00209-8
UR - https://doi.org/10.1186/s41120-026-00209-8
AB - Oligonucleotide therapeutics (ONTs) have revolutionized the medical landscape by enabling the precise modulation of genetic pathways. This perspective highlights the major conjugation strategies for ONTs, using antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) as representative modalities. We describe diverse classes of targeting ligands, including small molecules, cell-penetrating peptides (CPPs), antibodies, and aptamers. For example, triantennary N-acetylgalactosamine (GalNAc) conjugation has enabled a number of approved oligonucleotide therapeutics. Meanwhile, other emerging conjugation technologies have expanded oligonucleotide delivery to extrahepatic tissues to address a broader range of diseases. We further summarize the clinical translation of these delivery platforms, highlighting approved therapeutics alongside emerging clinical candidates. Finally, we provide an outlook on challenges and opportunities for the next generation of oligonucleotide therapeutics.
SN - 2364-9534
ER -